CLAIMS

1. Use of a Plasma Fraction in the manufacture of a medicament for treating a subject diagnosed with a cognitive impairment, wherein the medicament is to be administered using a Pulse Dosed dosing regimen, and wherein the Plasma Fraction is a Human Albumin Solution (HAS) comprising at least 95% albumin in relation to total protein.

2. The use of claim 1 wherein the HAS is a commercially available HAS.

3. The use of any of the preceding claims wherein the HAS is derived from plasma from a pool of humans 40 years of age or younger.

4. The use of any of the preceding claims wherein the HAS is produced from a human blood product.

5. The use of any of the preceding claims wherein the subject is monitored for improved cognitive function.

6. The use of any of the preceding claims wherein the subject is a mammal.

7. The use of claim 6 wherein the mammal is a human.

8. The use of any of the preceding claims wherein according to the Pulse Dosed dosing regimen the HAS is to be administered for five to seven consecutive days.

9. The use of any of the preceding claims wherein the effective amount of HAS is 100 ml.

10. The use of any of claims 1 to 8 wherein the effective amount of HAS is 250 ml.

11. The use of any of the preceding claims wherein the subject follows an exercise regimen after the Pulsed Dosed dosing regimen has been fully administered.

12. The use of any of claims 1 to 11 wherein the administering increases the number of synapses in the subject.

13. The use of any of claims 1 to 11 wherein the administering increases synaptic integrity of the subject.

14. The use of any of claims 1 to 11 wherein the administering increases neuronal network integrity of the subject.

15. The use of any of claims 1 to 11 wherein the administering increases neuronal connectivity of the subject.

16. A kit suitable for use in treating a subject for a cognitive disorder, the kit comprising a container comprising HAS as described in any of claims 1 to 4 and 7.